Incidence of diabetic ketoacidosis among patients with type 2 diabetes mellitus treated with SGLT2 inhibitors and other antihyperglycemic agents

Diabetes Research and Clinical Practice

Volumn 128, Issue , 2017, Pages 83-90

  Wang, Yiting ^a   Desai, Mehul ^a   Ryan, Patrick B ^a   DeFalco, Frank J ^a   Schuemie, Martijn J ^a   Stang, Paul E ^a   Berlin, Jesse A ^b   Yuan, Zhong ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b JOHNSON AND JOHNSON   (United States)

Author keywords

Ketoacidosis; Sodium glucose co transporter 2 (SGLT2) inhibitors; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; METFORMIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; SODIUM GLUCOSE COTRANSPORTER 2;

ADULT; ARTICLE; COHORT ANALYSIS; DIABETIC KETOACIDOSIS; DIABETIC PATIENT; FEMALE; HUMAN; INCIDENCE; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; ANTAGONISTS AND INHIBITORS;

COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC KETOACIDOSIS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85018539845     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2017.04.004     Document Type: Article

References (39)

1. [1] Gosmanov, A.R., Gosmanova, E.O., Dillard-Cannon, E., Management of adult diabetic ketoacidosis. Diabetes Metabolic Syndrome Obes: Targ Ther 7 (2014), 255–264.
2. [2] Gosmanov AR, Kitabchi AE. Diabetic ketoacidosis. In: De Groot LJ, Beck-Peccoz P, Chrousos G, Dungan K, Grossman A, Hershman JM, et al., editors. Endotext. South Dartmouth, MA; 2000.
3. [3] Xu, Y., Bai, J., Wang, G., Zhong, S., Su, X., Huang, Z., et al. Clinical profile of diabetic ketoacidosis in tertiary hospitals in China: a multicentre, clinic-based study. Diabet Med: J Br Diabet Assoc 33 (2016), 261–268.
4. [4] Kitabchi, A.E., Umpierrez, G.E., Murphy, M.B., Kreisberg, R.A., Hyperglycemic crises in adult patients with diabetes: a consensus statement from the American Diabetes Association. Diabetes Care 29 (2006), 2739–2748.
5. [5] Barski, L., Nevzorov, R., Harman-Boehm, I., Jotkowitz, A., Rabaev, E., Zektser, M., et al. Comparison of diabetic ketoacidosis in patients with type-1 and type-2 diabetes mellitus. Am J Med Sci 345 (2013), 326–330.
6. [6] Lam, K.S., Chow, C.C., Tan, K.C., Ma, R.C., Kong, A.P., Tong, P.C., et al. Practical considerations for the use of sodium-glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes. Curr Med Res Opin 32 (2016), 1097–1108.
7. [7] Rosenstock, J., Ferrannini, E., Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 38 (2015), 1638–1642.
8. [8] Rashid, O., Farooq, S., Kiran, Z., Islam, N., Euglycaemic diabetic ketoacidosis in a patient with type 2 diabetes started on empagliflozin. BMJ Case Rep, 2016, 10.1136/bcr-2016-215340 pii: bcr2016215340.
9. [9] Storgaard, H., Bagger, J.I., Knop, F.K., Vilsboll, T., Rungby, J., Diabetic ketoacidosis in a patient with type 2 diabetes after initiation of sodium-glucose cotransporter 2 inhibitor treatment. Basic Clin Pharmacol Toxicol 118 (2016), 168–170.
10. [10] Peters, A.L., Buschur, E.O., Buse, J.B., Cohan, P., Diner, J.C., Hirsch, I.B., Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 38 (2015), 1687–1693, 10.2337/dc15-0843.
11. [11] Erondu, N., Desai, M., Ways, K., Meininger, G., Diabetic Ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care 38 (2015), 1680–1686, 10.2337/dc15-1251.
12. [12] Wanner, C., Inzucchi, S.E., Lachin, J.M., Fitchett, D., von Eynatten, M., Mattheus, M., et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (2016), 323–334, 10.1056/NEJMoa1515920.
13. [13] Abdulrahman, G.O., Amphlett, B., Okosieme, O.E., Trends in hospital admissions with diabetic ketoacidosis in Wales, 1999–2010. Diabetes Res Clin Pract 100 (2013), e7–e10.
14. [14] Ginde, A.A., Pelletier, A.J., Camargo, C.A. Jr., National study of U.S. emergency department visits with diabetic ketoacidosis, 1993–2003. Diabetes Care 29 (2006), 2117–2119.
15. [15] Henriksen, O.M., Roder, M.E., Prahl, J.B., Svendsen, O.L., Diabetic ketoacidosis in Denmark: incidence and mortality estimated from public health registries. Diabetes Res Clin Pract 76 (2007), 51–56.
16. [16] Liu, C.C., Chen, K.R., Chen, H.F., Huang, H.L., Ko, M.C., Li, C.Y., Trends in hospitalization for diabetic ketoacidosis in diabetic patients in Taiwan: analysis of national claims data, 1997–2005. J Formos Med Assoc = Taiwan yi zhi. 109 (2010), 725–734.
17. [17] Lombardo, F., Maggini, M., Gruden, G., Bruno, G., Temporal trend in hospitalizations for acute diabetic complications: a nationwide study, Italy, 2001–2010. PLoS ONE, 8, 2013, e63675.
18. [18] Wang, J., Imai, K., Engelgau, M.M., Geiss, L.S., Wen, C., Zhang, P., Secular trends in diabetes-related preventable hospitalizations in the United States, 1998–2006. Diabetes Care 32 (2009), 1213–1217.
19. [19] Wang, Z.H., Kihl-Selstam, E., Eriksson, J.W., Ketoacidosis occurs in both type 1 and type 2 diabetes–a population-based study from Northern Sweden. Diabet Med: J Br Diabet Assoc 25 (2008), 867–870.
20. [20] Jensen, M.L., Persson, F., Andersen, G.S., Ridderstrale, M., Nolan, J.J., Carstensen, B., et al. Incidence of ketoacidosis in the Danish type 2 diabetes population before and after introduction of sodium-glucose cotransporter 2 inhibitors-a nationwide, retrospective cohort study, 1995–2014. Diabetes Care, 2017, 10.2337/dc16-2793 pii: dc162793 [Epub ahead of print].
21. [21] Elliott, J., Jacques, R.M., Kruger, J., Campbell, M.J., Amiel, S.A., Mansell, P., et al. Substantial reductions in the number of diabetic ketoacidosis and severe hypoglycaemia episodes requiring emergency treatment lead to reduced costs after structured education in adults with type 1 diabetes. Diabet Med: J Br Diabet Assoc 31 (2014), 847–853.
22. [22] Taylor, S.I., Blau, J.E., Rother, K.I., Perspective: SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metabolism, 2015, jc20151884.
23. [23] Ray, W.A., Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 158 (2003), 915–920.
24. [24] Voss, E.A., Makadia, R., Matcho, A., Ma, Q., Knoll, C., Schuemie, M., et al. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J Am Med Inf Assoc: JAMIA 22 (2015), 553–564.
25. [25] American Diabetes Association, Standards of medical care in diabetes-2015 abridged for primary care providers. Clin Diabet: Publ Am Diabet Assoc 33 (2015), 97–111.
26. [26] Cernea, S., Buzzetti, R., Pozzilli, P., Beta-cell protection and therapy for latent autoimmune diabetes in adults. Diabetes Care 32:Suppl. 2 (2009), S246–S252.
27. [27] Stone, M.A., Camosso-Stefinovic, J., Wilkinson, J., de Lusignan, S., Hattersley, A.T., Khunti, K., Incorrect and incomplete coding and classification of diabetes: a systematic review. Diabet Med: J Br Diabet Assoc 27 (2010), 491–497.
28. [28] Genkin, A., Lewis, D., Madigan, D., Large-scale Bayesian logistic regression for text categorization. Technometrics 49 (2007), 291–304.
29. [29] Austin, P.C., Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 10 (2011), 150–161.
30. [30] Schuemie, M.J., Ryan, P.B., DuMouchel, W., Suchard, M.A., Madigan, D., Interpreting observational studies: why empirical calibration is needed to correct p-values. Stat Med 33 (2014), 209–218.
31. [31] Boyce, R.D., Ryan, P.B., Noren, G.N., Schuemie, M.J., Reich, C., Duke, J., et al. Bridging islands of information to establish an integrated knowledge base of drugs and health outcomes of interest. Drug Saf 37 (2014), 557–567.
32. [32] Landin-Olsson, M., Latent autoimmune diabetes in adults. Ann N Y Acad Sci 958 (2002), 112–116.
33. [33] Peters, A.L., Henry, R.R., Thakkar, P., Tong, C., Alba, M., Diabetic ketoacidosis with canagliflozin, a sodium-glucose cotransporter 2 inhibitor, in patients with type 1 diabetes. Diabetes Care 39 (2016), 532–538.
34. [34] Thomas, C.C., Philipson, L.H., Update on diabetes classification. Med Clin N Am 99 (2015), 1–16.
35. [35] Umpierrez, G.E., Kitabchi, A.E., Diabetic ketoacidosis: risk factors and management strategies. Treat Endocrinol 2 (2003), 95–108.
36. [36] Mauvais-Jarvis, F., Sobngwi, E., Porcher, R., Riveline, J.P., Kevorkian, J.P., Vaisse, C., et al. Ketosis-prone type 2 diabetes in patients of sub-Saharan African origin: clinical pathophysiology and natural history of beta-cell dysfunction and insulin resistance. Diabetes 53 (2004), 645–653.
37. [37] Misra, S., Oliver, N., Dornhorst, A., Diabetic ketoacidosis: not always due to type 1 diabetes. BMJ (Clin Res Ed), 346, 2013, f3501.
38. [38] Hine, J., Paterson, H., Abrol, E., Russell-Jones, D., Herring, R., SGLT inhibition and euglycaemic diabetic ketoacidosis. Lancet Diabet Endocrinol, 2015.
39. [39] Gooderick D, Dashora U, Kumar S. Ketoacidosis in type 2 diabetes–is it type 1 and 1/2 diabetes? BMJ Case Rep; 2011.